In Other Journals

Ann Gregory
Med J Aust 2005; 183 (1): . || doi: 10.5694/j.1326-5377.2005.tb06873.x
Published online: 4 July 2005

A highly potent varicella-zoster vaccine has been reported to more than halve the incidence of herpes zoster and postherpetic neuralgia in healthy, older adults. In the US Shingles Prevention Study, 38 546 immunocompetent adults aged 60 years or older were randomised to receive either a live attenuated varicella-zoster vaccine derived from the Oka strain, or placebo, subcutaneously. The vaccine contained 18 700 to 60 000 plaque-forming units of virus, much more than the approximately 1350 plaque-forming units in the childhood vaccine. Over more than 3 years of follow-up, there were 957 cases of herpes zoster (315 among vaccine recipients and 642 among placebo recipients), and 107 cases of postherpetic neuralgia (27 among vaccine repicients and 80 among placebo recipients). Further, the vaccine reduced the severity of both conditions. At this stage, the "zoster vaccine" is investigational only.

  • Ann Gregory



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.